Intermittent Androgen Deprivation in Patients With Stage D2 Prostate Cancer, Phase III
Latest Information Update: 14 Dec 2023
At a glance
- Drugs Bicalutamide (Primary) ; Goserelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 24 Oct 2023 Results comparing treatment regimens androgen deprivation therapy or docetaxel in the control or research arms in mHSPC were utilized from 13 trials which includes (NCT00002651, NCT00216060, NCT00079001, NCT00104715, NCT00268476, NCT00309985, NCT00685646) studies, presented at the 48th European Society for Medical Oncology Congress.
- 13 Sep 2022 Results assessing whether castrate-resistant free survival and time to castrate-resistant disease are valid surrogates for OS from following clinical trials: NCT00002651, NCT00079001, NCT00104715, NCT00268476, NCT00309985, NCT00216060, ISRCTN38477744 and NCT00685646 presented at the 47th European Society for Medical Oncology Congress
- 04 Apr 2013 Status changed from active, no longer recruiting to completed.